Disclosed is a novel LXRβ agonist which is useful as a prophylactic and/or therapeutic agent for arteriosclerosis such as atherosclerosis and arteriosclerosis associated with diabetes, dyslipidemia, hypercholesterolemia, lipid-related diseases, inflammatory diseases induced by inflammatory cytokines, skin diseases such as allergic skin diseases, diabetes or Alzheimer’s disease. The LXRβ agonist is a carbinol compound represented by general formula (I), a salt of the carbinol compound, or a solvate of the carbinol compound or the salt.